An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma
Open Access
- 1 March 2024
- journal article
- research article
- Published by Elsevier in Cell Reports Methods
- Vol. 4 (3) , 100716
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinomaEuropean Journal of Cancer, 2022
- Advantages and drawbacks of dexamethasone in glioblastoma multiformeCritical Reviews in Oncology/Hematology, 2022
- Role of neutrophils in acute viral infectionImmunity, Inflammation and Disease, 2021
- Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progressionNature Communications, 2020
- Immune suppression in gliomasJournal of Neuro-Oncology, 2020
- Oncolytic Viruses and the Immune System: The Dynamic DuoMolecular Therapy - Methods & Clinical Development, 2020
- Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro SurgeryJournal of Neuro-Oncology, 2019
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018
- Immune regulation by glucocorticoidsNature Reviews Immunology, 2017
- Macrophage Colony-Stimulating Factor Is Required for Human Monocyte Survival and Acts as a Cofactor for Their Terminal Differentiation to Macrophages In VitroJournal of Leukocyte Biology, 1991